2026年7月11日-17日，全球医药市场共签署了21项资产授权和合作协议。中国市场共达成9项交易，包括2项引进交易、4项出海交易和3项国内交易。
国内市场上，本周最大的出海交易是迪哲医药与AstraZeneca就已获批资产sunvozertinib达成在全球范围内的独家授权许可协议，首付款6亿美元，总金额可达15亿美元。
国际市场上，本周共签署了12项资产授权和合作协议。就首付款而言，本周没有大型交易达成。
From July 11 to 17, a total of 21 agreements were signed worldwide. Within China’s biotech industry, there were two in-licensing deals, four out-licensing deals and three domestic transactions.
In China, the largest out-licensing deal involved DizalPharma and AstraZeneca for the approved asset sunvozertinib, with an upfront payment of $600 million and a total deal value of $1.5 billion.
Globally, 12 deals were announced. Although none of the transactions disclosed major headline financial terms during this period, they reflect ongoing strategic partnership activity across the industry.
3. M&A Deals
4. Top Deals of 2026
